Logo

American Heart Association

  2
  0


Final ID: 4141686

Chromatin Remodeling Drives Immune-Fibroblast Cell Communication in Heart Failure

Abstract Body (Do not enter title and authors here): Chronic inflammation and tissue fibrosis are common stress responses that worsen organ function, yet the molecular mechanisms governing their crosstalk are poorly understood. In diseased organs, stress-induced changes in gene expression fuel maladaptive cell state transitions and pathological interaction between diverse cellular compartments. Although chronic fibroblast activation worsens dysfunction in the lung, liver, kidney, and heart, and exacerbates many cancers, the stress-sensing mechanisms initiating the transcriptional activation of fibroblasts are not well understood. Here, we show that conditional deletion of the transcription co-activator Brd4 in infiltrating Cx3cr1-positive myeloid cells ameliorates heart failure and is associated with a dramatic reduction in fibroblast activation. Analysis of single-cell chromatin accessibility and BRD4 occupancy in vivo in Cx3cr1-positive cells identified a large enhancer proximal to Interleukin-1 beta (Il1b), and a series of CRISPR deletions revealed the precise stress-dependent regulatory element that controls expression of Il1b in disease. Secreted IL1B functioned non-cell autonomously to activate a p65/RELA-dependent enhancer near the transcription factor MEOX1, resulting in a profibrotic response in human cardiac fibroblasts. In vivo, antibody-mediated IL1B neutralization improved cardiac function and tissue fibrosis in heart failure. Mechanistically, systemic IL1B inhibition or targeted Il1b deletion in Cx3cr1-positive cells prevented stress-induced expression of MEOX1 and inhibited fibroblast activation. The elucidation of BRD4-dependent crosstalk between a specific immune cell subset and fibroblasts through IL1B provides mechanistic insights into how inflammation drives profibrotic cell states and presents new therapeutic strategies for heart disease and other chronic inflammatory disorders featuring maladaptive tissue remodeling.
  • Alexanian, Michael  ( Gladstone Institutes , San Francisco , California , United States )
  • Auclair, Kirsten  ( Gladstone Institutes , San Francisco , California , United States )
  • Zhu, Ada  ( Gladstone Institutes , San Francisco , California , United States )
  • An, Yuqian  ( Gladstone Institutes , San Francisco , California , United States )
  • Ekstrand, Christina  ( UCSF , San Francisco , California , United States )
  • Martinez, Cassandra  ( UCSF , San Francisco , California , United States )
  • Gonzalez Teran, Barbara  ( Gladstone Institutes , San Francisco , California , United States )
  • Flanigan, Will  ( Gladstone Institutes , San Francisco , California , United States )
  • Kim, Charis  ( Gladstone Institutes , San Francisco , California , United States )
  • Conradson, Devon  ( University of Colorado Anschutz , Aurora , Colorado , United States )
  • Gardner, Zachary  ( University of Pennsylvania Philadelphia , Philadelphia , Pennsylvania , United States )
  • Padmanabhan, Arun  ( UCSF , San Francisco , California , United States )
  • Li, Li  ( University of Pennsylvania Philadelphia , Philadelphia , Pennsylvania , United States )
  • Costa, Mauro  ( Gladstone Institutes , San Francisco , California , United States )
  • Jain, Rajan  ( University of Pennsylvania Philadelphia , Philadelphia , Pennsylvania , United States )
  • Charo, Israel  ( Gladstone Institute , San Francisco , California , United States )
  • Combes, Alexis  ( UCSF , San Francisco , California , United States )
  • Haldar, Saptarsi  ( Amgen , S San Fran , California , United States )
  • Pollard, Katherine  ( Gladstone Institute , San Francisco , California , United States )
  • Vagnozzi, Ronald  ( University of Colorado Anschutz , Aurora , Colorado , United States )
  • Mckinsey, Timothy  ( UNIVERSITY OF COLORADO DENVER , Aurora , Colorado , United States )
  • Przytycki, Pawel  ( Gladstone Institutes , San Francisco , California , United States )
  • Nishino, Tomohiro  ( Gladstone Institute , San Francisco , California , United States )
  • Srivastava, Deepak  ( GLADSTONE INSTITUTES , San Francisco , California , United States )
  • Travers, Joshua  ( University of Colorado Anschutz , Aurora , Colorado , United States )
  • Ye, Lin  ( Gladstone Institutes , San Francisco , California , United States )
  • Angelo, Pelonero  ( Gladstone Institutes , San Francisco , California , United States )
  • Lee, Clara  ( Gladstone Institutes , San Francisco , California , United States )
  • Sadagopan, Nandhini  ( Gladstone Institute , San Francisco , California , United States )
  • Huang, Yu  ( Gladstone Institutes , San Francisco , California , United States )
  • Author Disclosures:
    Michael Alexanian: DO NOT have relevant financial relationships | Kirsten Auclair: No Answer | Ada Zhu: No Answer | Yuqian An: No Answer | Christina Ekstrand: DO NOT have relevant financial relationships | Cassandra Martinez: DO NOT have relevant financial relationships | Barbara Gonzalez Teran: No Answer | Will Flanigan: DO NOT have relevant financial relationships | Charis Kim: DO NOT have relevant financial relationships | Devon Conradson: DO NOT have relevant financial relationships | Zachary Gardner: No Answer | Arun Padmanabhan: DO NOT have relevant financial relationships | Li Li: DO NOT have relevant financial relationships | Mauro Costa: DO NOT have relevant financial relationships | Rajan Jain: DO NOT have relevant financial relationships | Israel Charo: DO NOT have relevant financial relationships | Alexis Combes: No Answer | Saptarsi Haldar: No Answer | Katherine Pollard: No Answer | Ronald Vagnozzi: DO have relevant financial relationships ; Individual Stocks/Stock Options:Edwards Lifesciences:Active (exists now) | Timothy McKinsey: No Answer | Pawel Przytycki: DO NOT have relevant financial relationships | Tomohiro Nishino: DO NOT have relevant financial relationships | Deepak Srivastava: DO have relevant financial relationships ; Other (please indicate in the box next to the company name):Tenaya Therapeutics - co-founder, board member, stockholder, scientific advisory board member:Active (exists now) | Joshua Travers: DO NOT have relevant financial relationships | Lin Ye: DO NOT have relevant financial relationships | Pelonero Angelo: No Answer | Clara Lee: No Answer | Nandhini Sadagopan: No Answer | Yu Huang: DO NOT have relevant financial relationships
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:
More abstracts on this topic:
A Case of Dilated Cardiomyopathy and Systemic Thromboembolism in a Young Patient on Testosterone Replacement Therapy

Sabri Muhammad, Ijaz Naila, Nadeem Ramsha, Checchio Lucy, Riaz Faiza

Association of Left Atrial Fibrosis with AF Burden Post-Ablation: Insights from the DECAAF II Study

Younes Hadi, Lim Chanho, Rao Swati, Tirado Polo Francisco, Liu Yingshuo, Jia Yishi, Tsakiris Eli, Assaf Ala', Ademi Besim, Shamaileh Ghaith, Hui Yanpei, Mahnkopf Christian, Donnellan Eoin, Pandey Amitabh, Marrouche Nassir, Noujaim Charbel, Bidaoui Ghassan, Bsoul Mayana, Feng Han, El Hajjar Abdel Hadi, Mekhael Mario, Dagher Lilas

More abstracts from these authors:
3D Genome Organization in Cardiac Development and Disease

Jain Rajan

A CRISPR-Activation CROP-seq Screen Identifies HMGN1 as a Dosage-Sensitive Regulator of Heart Defects in Down Syndrome

Ranade Sanjeev, Mital Rahul, Boileau Ryan, Koback Frances, Padmanabhan Arun, Merriman Alexander, Wallace Langley, Nguyen Annie, Poulis Nikolaus, Gifford Casey, Pollard Katherine, Li Feiya, Srivastava Deepak, Whalen Sean, Angelo Pelonero, Ye Lin, Huang Yu, Brand Abigail, Nishino Tomohiro, Costa Mauro

You have to be authorized to contact abstract author. Please, Login
Not Available